EFFECT Trial: Efficacy of Flucytosine & Fluconazole as Early Cryptococcal Treatment. Phase 3 RCT at 13 sites in South Africa, Tanzania, Vietnam. Funded @The_MRC
We are thrilled to share that we are down to double digits! 99 participants left to reach out recruitment target of 600. Looking forward to contributing meaningful data to help to #EndCryptoDeaths 🦠🏥💯
@neleshg@sile47742@JNJarvis76 @KylaMurphyZA
We are thrilled to share our latest EFFECT newsletter, which can be viewed here:
https://t.co/fO3RA03PfG
Take a look at what we've been up to over the past few months to #EndCryptoDeaths
@neleshg @KylaComins & Michelle are in Dar es Salaam with our @NIMR_Tanzania team for a routine monitoring visit this week.
At the same time, we celebrate 200 participants enrolled onto EFFECT across all sites- congratulations to the teams for the great work to #EndCryptoDeaths
https://t.co/b7U4jseioY
Take a look at what we've been up to, in our latest EFFECT newsletter! It's been an exciting few months, and we are looking forward to an inspired 2024, working to #EndCryptoDeaths
Thrilled that today @JNJarvis76 and I were able to represent the huge and wonderful @ambitioncm2020 team and receive the @EACSociety European Hector Research Award for best clinical/epidemiological paper in HIV in the last two years. Dedicated to all participants #EACS2023
A fantastic morning today, hearing from our Community Advisory Board and a study participant's perspective, reminding us of the importance of ensuring we translate our work from bench to bedside, to #endcryptodeaths
Our second Investigators Meeting starts in Cape Town today! Wonderful to have so many team members here in person, looking forward to a fantastic few days of reflection, collaboration and inspiration for the way forward to #endcryptodeaths
Is fluconazole enough for cryptococcal antigenaemia? The @EffectTrial is exploring the impact of flucytosine plus fluconazole in South Africa and Tanzania. Thrilled to be part of this wonderful team!
St George’s researchers are leading an international trial which aims to improve treatment to prevent a type of meningitis that attacks the brain in people with advanced HIV, thanks to £4.5m funding from @The_MRC.
Learn more about the @EffectTrial: https://t.co/6DuMLtURil
We're pleased to share the 3rd edition of our EFFECT newsletter, which can be viewed here: https://t.co/MHatzjdPlL
And a massive congratulations to our sites for reaching 100 enrolled participants, a fantastic achievement towards our goal to #endcryptodeaths. Onward to 600!
Incredible week at the #ICCC in Kampala. Glastonbury for #cryptococcus! Great to connect with amazing colleagues, make new friends and discuss future collaborations. Phenomenal organisation by the team!
Valuable insights from @drdavidlawrence on patient perspectives of the @ambitioncm2020 regimen.
Bottom line: staff and patients prefer a single dose of L-Amb.
"They want one yellow, not 7 yellows"💉🟡
Now to push for implementation with @SHARECM1 and @IMPRINT_NIHRGHR
🧫🦠🧠
@JNJarvis76 taking us through the "bench to bedside" pipeline for the @ambitioncm2020
An excellent model, and reminder that the work is far from done when the clinical trial is finished.
We need access, advocacy and engagement if we want to #endcryptodeaths by 2030🧫🦠🧠
Our co-CI @neleshg presenting on CrAg screening programmes, in which the EFFECT trial is embedded. Our other co-CI @Molloy_Sile presented @EffectTrial earlier this morning during the #ICCC2023 Clinical Track CrAg Screening sessions. Working our way to #endcryptodeaths by 2030💉💊
Many of our investigators are participating in #ICCC2023 in Kampala this week. Today, a master class in the clinical management of cryptococcal meningitis with @drdavidlawrence @KylaComins and colleagues from @SHARECM1 discussing implementation of the @ambitioncm2020 regimen 💊💉